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P. aeruginosa is the most significant pathogen in CF lung disease. Chronic infection is preceded by a period of intermittent
colonization. Early aggressive antimicrobial treatment at initial detection of P. aeruginosa in lower respiratory tract (LRT) secretions can
prevent transition to chronic infection in approximately 80% of the patients, while the rest progress to chronic infection in spite of
treatment. To analyze risk factors for development of chronic infection, a cohort of 89 CF patients free of chronic infection at the study
period start was followed for 10 years.
28 of the patients (study group) developed chronic infection in spite of early treatment and 28 age-matched patients who did not (controls)
were included in the analysis.
During the 3 years period prior to onset of chronic infection, P. aeruginosa-positive cultures were more frequent in the study group than in
the controls (2.2 vs. 0.5 per year, p <0.0001). Growth of mucoid strains of P. aeruginosa was more frequent in study group than in controls
(11.5% vs. 0%, p <0.0001). Most important, specific anti-pseudomonal IgG serum antibodies were significantly higher in the study group
than in controls (0.98 Elisa Units vs. 0.53, p =0.04) already 3 years prior to onset of chronic infection and increased 0.44 EU pr year in the
study group but remained at the initial level in the control group ( p <0.005). Occurrence of Aspergillus-positive cultures were significantly
more frequent in the study group than in controls ( p =0.01).
The strongest risk factor for development of chronic P. aeruginosa infection was increasing levels of specific anti-pseudomonal
antibodies, specifically of IgG1 and IgG4 subclass and total anti-Pseudomonas IgG, 3 years prior to onset of chronic infection, with odds
ratio (OR) 8.9, 7.7 and 7.4, respectively ( p <0.005), and growth of mucoid P. aeruginosa strains with OR of 7.4, p =0.006). Occurrence of
Aspergillus was also a risk factor for developing chronic P. aeruginosa infection with the OR of 4.7 ( p =0.008).
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The bronchopulmonary disease in cystic fibrosis (CF)
evolves predominantly as a lower respiratory infection
leading to progressive obstructive lung disease [1]. The
lungs of CF infant are nearly normal at birth but subsequently
there is rapid onset of infection and inflammation. Inflam-1569-1993/$ - see front matter D 2005 European Cystic Fibrosis Society. Publish
doi:10.1016/j.jcf.2005.11.002
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E-mail address: tania@rh.dk (T. Pressler).mation begins at an early age and progresses throughout life,
ultimately leading to lung tissue destruction [1,2–6]. The
initial pathogens are often Staphylococcus aureus and
Haemophilus influenzae but bronchoscopic studies have
confirmed that P. aeruginosa infection may also be an early
event [7]. Chronic pulmonary infection with P. aeruginosa
develops in most patients with CF; by adulthood 80% of
patients are infected in most CF centers and chronic P.
aeruginosa infection is the primary cause of increased
morbidity and mortality in CF [8–11].is 5 (2006) 9 – 15ed by Elsevier B.V. All rights reserved.
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stage of intermittent colonization for an average duration of
12 months [12].
P. aeruginosa strains found early in CF patients resemble
those in the environment being relatively sensitive to
antibiotics, having smooth lipopolysaccharide (LPS) con-
taining O-chains and being of non-mucoid phenotype. The
bacterial population adaptates to the environments within
the respiratory and conductive zones of the lungs of CF
patients [13]. The P. aeruginosa phenotype becomes LPS-
rough and highly mucoid due to production of alginate and
in consequence the production of biofilm which protects the
microcolonies from action of antibiotics and host immune
response [13,14–16].
Attempts have been made to prevent or postpone chronic
bronchopulmonary P. aeruginosa infection in CF [17–22]
and the results are very encouraging. In a Danish study, after
an observation period of 44 months only 16% of the patients
became chronically infected with P. aeruginosa compared
with 72% of historical controls [18]. Since 1989 early
intervention at the time of first acquisition of P. aeruginosa
and again each time P. aeruginosa was isolated from the
airway secretions has been a standard treatment in Copen-
hagen CF centre. The purpose of the present case control
study is to define the possible risk factors for development
of chronic P. aeruginosa infection despite vigorous antimi-
crobial treatment [18].2. Materials and methods
2.1. Study design
In January 1990, 225 CF patients were followed at
Copenhagen CF centre. 89 patients were without any chronic
lower respiratory tract infection. CF was diagnosed with
standard criteria [23]. All patients were controlled on a
regular monthly basis in the out-patient clinic. At each visit
the clinical condition, pulmonary function and sputum
bacteriology were examined and have thus been recorded
prospectively since 1970. Serum samples were collected at
intervals of 3–4 months and evaluated for anti-P. aeruginosa
antibody levels [24,25]. All patients have since 1989 been
treated according to the protocol of early eradication of initial
colonization with P. aeruginosa. The strategy employed is
based upon regular monthly control, which includes sam-
pling of sputum or nasolaryngeal secretions for microscopy
and culture and with treatment whenever P. aeruginosa is
identified using a combination of inhaled colistin and oral
ciprofloxacin [18]. In the 10 years period, 28 of 89 patients
included in this study developed a chronic infection with P.
aeruginosa. Chronic P. aeruginosa infection was defined as
persistent presence of P. aeruginosa in sputum obtained by
expectoration or nasolaryngeal suction for 6 consecutive
months or less when levels of precipitating anti-Pseudomo-
nas antibodies were 2 precipitins [24].An age-matched control group of 28 CF patients who, at
the end of the study period, were still free of chronic
infection were randomly selected from a study population.
The patients with the age closest to the age of index patients
were selected. Study period for each index patient and the
matched control patient was a period of three years prior to
development of chronic P. aeruginosa infection for the
index patient. CF genotype, MBL genotype, sex, forced
expiratory volume in one second (FEV1) [26], weight and
height expressed as BMI z-score [27], occurrence of S.
aureus, Aspergillus fumigatus and P. aeruginosa in lower
respiratory tract in whole study period were recorded from
the medical records.
2.2. Bacteriology
Sputum or lower respiratory tract secretion obtained by
endo-laryngeal suction was processed for Gram-staining and
microscopy and culture as detailed previously [28]. P.
aeruginosa and other microorganisms were identified as
previously described [28].
2.3. Specific anti-Pseudomonas antibodies
Specific IgG anti-Pseudomonas antibodies were mea-
sured at least once a year by crossed immunoelectropho-
resis [29]. Furthermore, the Pseudomonas specific IgG and
IgG subclass 1–4 were assayed by ELISA [25]. Water
soluble antigens were produced by sonication from each of
17 serotypes of the international antigen typing scheme of
P. aeruginosa, equal volumes of each were mixed and
designated standard antigen (St-Ag), protein concentration
9 g/L. The assay was calibrated by using a standard of
pooled serum from 10 chronic infected patients with CF.
Results were expressed as ELISA units (EU) and
calculated in relation to the standard, which was given
an arbitrary value of 100 EU [25]. In order to establish
normal values for the ELISA assays sera from 143 healthy
subjects (mean age 10.1 years; range 0.1–26.8 years) and
64 CF patients (mean age 9.4 years; range 1.6–34.5 years)
without history of P. aeruginosa positive LRT secretions
were investigated.
2.4. Mannose-binding lectin (MBL2) genotypes
MBL2 genotypes were investigated by a PCR sequence
specific priming method [30]. Structural variant alleles in
codons 52 (D), 54 (B) and 57 (C), respectively, were pooled
into an O allele, because of the similar reducing effect on the
mannose-binding lectin serum concentration. The normal
allele is named A.
2.5. Statistics
Comparison between case and controls were made
using Wilcoxon matched pairs signed rank sum test for
Table 2
Levels of specific anti-Pseudomonas antibodies
Mean Mean+1SD Median 90th percentile
a) CF patients without history of P. aeruginosa positive culture
IgG 0.576 1.501 0.315 1.169
IgG1 0.241 0.567 0.095 0.725
IgG2 0.090 0.237 0.0 0.259
IgG3 0.194 0.567 0.125 0.43
T. Pressler et al. / Journal of Cystic Fibrosis 5 (2006) 9–15 11continuous data and Fisher exact test for categorical data.
A stepwise logistic regression model was used to
determine risk factor for acquisition of chronic P.
aeruginosa infection. A p value 0.05 was considered
statistically significant. For significant variables on step-
wise logistic regression, the odds ratio (OR) with 95%
confidence intervals were calculated.IgG4 0.038 0.103 0.0 0.11
b) Healthy controls
IgG 0.66 1.13 0.53 1.41
IgG1 0.29 0.72 0.0 0.76
IgG2 0.048 0.207 0.0 0.16
IgG3 0.127 0.508 0.0 0.45
IgG4 0.0 0.0 0.0 0.03. Results
3.1. Patients
The gender, CFTR mutations and MBL2 genotypes are
shown in Table 1b. No significant differences were found,
however, 12 (43%) of 28 index patients were carriers of
MBL variant alleles compared to 6 (21%) of 28 controls
(n.s). The nutritional status of both groups was not different
from a healthy population [27] (Table 1a).
The lung function (average of all measurements in a one
year) was significantly lower in the study group 3 years
prior to onset of chronic infection, median FEV1 was 75%
of predicted in study group versus 87% in controls
( p =0.04). Lung function improved in the study group and
at onset of chronic infection FEV1 was 82% in the study
group versus 87% in the controls (n.s).
3.2. Bacteriology
The median age at first isolate of P. aeruginosa was
5.1 and 5.9 years, respectively, in study group and
controls (n.s.). The number of P. aeruginosa positive
culture was summed up for all study patients, in the three
years period prior to the start of chronic infection for the
case group. The P. aeruginosa-positive cultures were
more frequent in the study group, median 2.2 (22% of allTable 1
Baseline demographics of the CF study group and CF control group
a)
Age (years) at start of chronic infection for the study group
BMI z-score 2 years before
BMI z-score 1 year before
BMI z-score at infection start
Frequency of S. aureus positive culture per patient in 3 years study period
Frequency of Aspergillus positive culture pr patient in 3 years study period
Percent mucoid strains of P. aeruginosa
Age at first isolate of P. aeruginosa (years)
Frequency of P. aeruginosa positive culture in 3 years study period
b)
Study group
Gender M/F total 11/17
MBL variant alleles 12
CFTR mutation mild/severe 0/28sputum samples) per year versus 0.5 (5% of all samples)
per year in controls ( p <0.0001). Growth of mucoid
strains of P. aeruginosa was more frequent in the study
group than in controls (11.5% of isolates versus 0%,
p <0.0001) (Table 1a). Logistic regression analysis
showed that the occurrence of mucoid phenotype of
bacteria was a risk factor for developing chronic P.
aeruginosa infection with the OR of 7.4 (95% CI 1.8–
30.7, p =0.006).
Positive cultures with S.aureus were equally distributed
in both investigated groups (Table 1). On the other hand
occurrence of Aspergillus-positive cultures were significant-
ly more frequent in the study group than in controls
( p =0.01) (Table 1a). Logistic regression analysis showed
that the occurrence of of Aspergillus is a risk factor for
developing chronic P. aeruginosa infection with the OR of
4.7 (95% CI 1.5–15, p=0.008). Allergic bronchopulmonary
aspergillosis (ABPA) was diagnosed in two cases in the
study group and in one control patient.Study group (N =28) Control group (N =28) p value
Median Range Median Range
13.6 2.6–27.8 12.2 2.9–26.1 Ns
0.3 2.2–2.3 0.13 2.8–1.4 Ns
0.4 2.1–2.3 0.0 1.3–1.6 Ns
0.35 2.2–2.0 0.08 1.4–1.4 Ns
10.7 0–23 10.6 1–21 Ns
8 0–32 1 0–29 0.01
11.5 0–67 0 0–0.1 <0.0001
5.1 0.4–27.1 5.9 0.3–28.1 Ns
2.2 0–9.4 0.5 0–3.3 <0.0001
Control group p value
15/13 Ns
6 Ns
3/25 Ns
Table 3
Development of IgG and IgG subclass anti-Pseudomonas specific anti-
bodies in the CF study group and the CF control group
Study group Control group p value
Median Range Median Range
IgG
3 years before 0.98 0.57–2.97 0.56 0–2.97 0.04
2 years before 1.31 0.57–3.07 0.51 0.19–7.6 0.0002
1 year before 1.54 0.25–2.87 0.52 0–1.6 0.0002
At infection start 2.44 0.67–5.0 0.61 0.16–1.58 <0.001
IgG1
3 years before 0.79 0.4–2.36 0.34 0.0–1.7 0.003
2 years before 1.0 0.41–6.23 0.35 0.0–1.48 <0.001
1 year before 1.13 0.42–3.44 0.35 0.0–1.3 <0.001
At infection start 1.75 0.71–10.5 0.31 0.0–1.7 <0.001
IgG2
3 years before 0.25 0.0–2.5 0.02 0.0–0.75 0.04
2 years before 0.24 0.03–2.64 0.0 0.0– .60 0.0005
1 year before 0.39 0.01–16.5 0.0 0.0–0.75 0.0002
At infection start 0.44 0.0–5.0 0.21 0.0–1.78 0.002
IgG3
3 years before 0.33 0.0–5.8 0.0 0.0– .7 0.01
2 years before 0.32 0.2–8.4 0.0 0.0–1.33 <0.001
1 year before 0.3 0.0–8.4 0.0 0.0–3.8 0.0005
At infection start 0.53 0.0–14.5 0.19 0.0–1.25 <0.001
IgG4
3 years before 0.16 0.0– .30 0.0 0.0–0.51 0.02
2 years before 0.18 0.0–1.34 0.0 0.0–0.37 <0.001
1 year before 0.18 0.0–1.82 0.0 0.0–0.31 <0.001
at infection start 0.23 0.09–4.8 0.0 0.0–0.21 <0.001
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Fig. 1. Changes (EU per year) in specific anti-pseudomonal IgG levels in 3
years study period in a) the CF study group who developed chronic P.
aeruginosa compared to the b) the CF control group (median and 95th
percentile).
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There were no statistical significant differences between
levels of specific anti-Pseudomonas antibodies in healthy
controls and CF patients without history of P. aeruginosa
positive cultures (Table 2a and b).
On the other hand the specific anti-pseudomonal serum
antibodies of total IgG and each IgG subclasses were
significantly higher in the study group than in controls
already 3 years prior to onset of chronic infection and
continued to increase through whole study period (Table 3).
The anti-Pseudomonas IgG and IgG1 increased with median
0.44 EU per year (range 0.4 to 2.0) and 0.3 EU per year
(1.9 to 3.2), respectively, in the study group compared to
0.0 EU per year (0.4 to 1.4, and 0.2 to 0.3) for both IgG
and IgG1 (p<0.005) in control group (Fig. 1). Changes in
IgG2, IgG3 and IgG4 levels were not significantly different
between case and control groups. Logistic regression analysis
showed that the strongest risk factor for developing chronic P.
aeruginosa infection was elevated levels of specific anti-
pseudomonal antibodies of IgG1and IgG4 subclasses already
3 years prior to onset of chronic infection, with OR 8.9 (95%
CI 2.3–60, p =0.0035) and 7.7 (95% CI 1.9–41.7,
p=0.005), respectively, and elevated total anti-PseudomonasIgG levels two years before onset of chronic infection with
OR 7.4 (95% CI 1.9–28, p=0.004).4. Discussion
P. aeruginosa infection in patients with CF is associated
with deteriorating lung function and increased morbidity
[1,31–34].
The attempt has been made to define the risk factors for
initial acquisition of P. aeruginosa in children with CF [35–
38] and the risk factors turned out to include S. aureus
infection [38] and chronic anti-staphylococcal antibiotic
treatment [36,37], female gender, delta F508 homozygous
genotype [38] and attendance at cystic fibrosis clinic
[35,36], and viral infections [12].
In our population the sex of the patients has not shown to
be a risk factor for acquisition of P. aeruginosa infection.
The occurrence of severe CFTR mutation was not recog-
T. Pressler et al. / Journal of Cystic Fibrosis 5 (2006) 9–15 13nized as a risk factor, but the prevalence of mild CFTR
mutations in our patient population is very low [39].
MBL2 variant alleles have previously shown to have an
impact on the disease course of Danish CF patients, but not
on the acquisition of P. aeruginosa [40]. In the present
matched case control study we did not observe an increased
frequency of index cases carrying MBL2 variant alleles
compared with controls, though the power of the current
study was limited by its small sample size. To evaluate this
further, larger matched case control studies are needed
before a conclusion can be drawn whether mannose-binding
lectin plays a role in susceptibility for P. aeruginosa in CF
patients.
Maselli et al. [38] found that colonization with S. aureus
were associated with an earlier acquisition of P. aeruginosa.
Distinction between chronic infection and intermittent
colonization was not made. In our study the study
population harbored S. aureus as often as controls, in an
average 11 times in the three-year study period (Table 1).
All S. aureus isolated were treated with relevant antibiotics
according to the current resistance pattern. The use of anti-
staphylococcal antibiotics was not different in both groups
and neither isolation nor treatment of S. aureus came out as
a risk factor.
Attendance to the CF clinic not practicing cohort
segregation and exposure to P. aeruginosa-positive patients
have been reported as risk factors for early P. aeruginosa
acquisition [35]. Evidence for transmission of P. aeruginosa
between CF patients is well established [41–44]. Cohort
isolation of patients with CF according to their colonization
status has been the policy in our CF Center since 1981 [45].
It can explain why contact to the CF clinic is not anymore a
risk factor in our CF population.
In our study occurrence of Aspergillus-positive cultures
were significantly more frequent in the study group than in
controls. Logistic regression analysis showed that the
occurrence of Aspergillus is a risk factor for developing
chronic P. aeruginosa infection. A similar observation was
made by Graff and Burns [46] when they studied factors
affecting the incidence of Stenotrophomonas maltophilia in
CF. The other factor they found having an impact on
incidence of S. maltophilia was the use of antibiotics,
particularly oral fluroquinolones. The occurrence of Asper-
gillus as a risk factor for P. aeruginosa chronic infection in
our study may reflect more frequent use of antibiotics in the
study group compared to the controls. As only 2 of the CF
patients of the study group and one of the control group
developed ABPA, steroid treatment of this disease cannot be
responsible risk factor. P. aeruginosa were more frequently
found in the study group than in the control group and
because of our policy to treat P. aeruginosa every time this
microorganism appears in respiratory tract secretions the
study population had a significant higher antibiotic require-
ments. The observation of reduced lung function in a group
of patients who subsequently developed P. aeruginosa
infection have been made before [47,48], and confirmedin the present study. Poorer lung function in the study group
indicates pre-existing lung damage when compared with
patients who remained free of P. aeruginosa.
It has been known for many years that chronic P.
aeruginosa infection preceded by intermittent colonization
[12,49] and the most characteristic feature of chronic P.
aeruginosa infection is the production of alginate (respon-
sible for the mucoid phenotype) and simultanously biofilm
formation. The transition to the mucoid variant correlates
with development of a pronounced antibody response and a
poor prognosis [8,48,50,51]. Growth of mucoid strains of P.
aeruginosa was more frequent in the study group than in
controls and occurrence of mucoid phenotype of bacteria was
a risk factor for developing chronic P. aeruginosa infection
with the OR of 7.4. It has been shown in vitro, that P.
aeruginosa growing in alginate biofilms is highly resistant to
antibiotics and protected against phagocytosis [52–55].
The most important results of this study are the
observation on differences between specific anti-Pseudomo-
nas antibody levels in case and control groups. Specific anti-
pseudomonal IgG serum antibodies were significantly higher
in the study group than in controls already 3 years prior to
onset of chronic infection and increased significantly
through the whole study period in the study group but
remained at the initial level in the control group. The
strongest risk factor for developing of chronic P. aeruginosa
infection was increasing levels of specific anti-pseudomonal
antibodies already 3 years prior to onset of chronic infection.
The results show that antibody measurement have
potential diagnostic value and can be used as a prognostic
tool for identification of the group of CF patients at risk of
establishing chronic P. aeruginosa infection. Specially
increasing levels of specific anti-Pseudomonas IgG anti-
bodies seem to be a useful parameter to select the patients
being at risk to develop a chronic infection. We recommend
that specific anti-P. aeruginosa antibodies should be
measured regularly and at least once a year in all CF
patients and more frequently in individual patients when P.
aeruginosa has been intermittently isolated. This diagnostic
approach in combination with aggressive anti-pseudomonal
treatment of patients with increasing antibody levels and/or
with occurrence of mucoid phenotype of the microorgan-
isms, will hopefully lead to further reduction in prevalence
of chronic P. aeruginosa infection.References
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